Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Dragnev, D ^a   Barr, D ^a   Kulshrestha, M ^a   Shanmugalingam, S ^a  

^a HYWEL DDA UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRINZOLAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; ETANERCEPT; LOTEPREDNOL;

ADULT; ARTICLE; CASE REPORT; CHORIORETINITIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; EYE EXAMINATION; FEMALE; HUMAN; LYMPHADENOPATHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOID PANUVEITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL FIELD;

EID: 84885451734     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-200552     Document Type: Article

References (16)

1. Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm 2012;20:44-8.
2. Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol 2009;53:439-40.
3. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21:645-6. (Pubitemid 37236461)
4. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicentre active-surveillance report. Arthritis Rheum 2003;48:2122-7. (Pubitemid 36959191)
5. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36-42. (Pubitemid 20044133)
6. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997;156:1586-92. (Pubitemid 27505529)
7. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40. (Pubitemid 36427629)
8. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85. (Pubitemid 36851350)
9. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmol 2003;113:2317-23.
10. Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag 2008;4:1305-13.
11. Prasse A, Georges CG, Biller H, et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol 2000;122:241-8.
12. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(5 Suppl 1):34-8.
13. Moustou A-E, Matekovits A, Dessinioti C., et al Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinic review. J Am Acad Dermatol 2009;61:486.
14. Sieper J, Van den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005;34:23-7.
15. Tong D, Manolios N, Howe G. et al. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J 2012;42:89-94.
16. Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol 2012;39:289-93.